Private Placements, Capital Formation,
Restructuring & Recapitalizations



Pure Bioscience ~ $8,400,000 Common Stock & Warrants ~ October 2007

PURE Biosciences patented new antimicrobial molecule, silver dihydrogen citrate (SDC), is stabilized ionic silver that can serve as a platform technology. It is distinguishable from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. Currently used as a powerful hard surface disinfectant, PURE is developing term revenue opportunities for SDC as an active ingredient in other products.

After leading a successful offering for the Company last year, Taglich executed this larger transaction of common stock with warrants at higher price levels and valuation. Together, these two offerings provide PURE with the necessary capital to fully advance its business strategy and pursue the listing of its stock on a national exchange. Being able to help clients as they grow is just another example of Taglich Brothers’ commitment and support.

The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.